Management Team
Daniel D. Adams, JD
Chairman of the Board, Interim Director of Business Development and Strategic Planning
Dan joined Protein Sciences as CEO in 1996. He previously founded and managed biopharmaceutical companies that have a combined market value of over $30 billion. Dan co-founded Biogen (OTC:BGEN) in 1976 and served as its first President and CEO, was founder and CEO of Advanced Genetic Sciences Inc. (OTC:AGSI) in 1980, was co-founder and Managing Director of Plant Genetic Systems in 1982, and founded and was CEO of AlleRx in 1989.
Drs. Manon M. J. Cox, MBA
Chief Executive Officer
Manon became Chief Operating Officer in 2002. She joined Protein Sciences in 1998 as Director of Business Development. Previously she was with Gist-brocades, a large Dutch company specialized in fermentation, where she held various management positions including VP, Business Development. Since 2006, she has also served on the Scientific Advisory Board of Pall BioPharmaceuticals.
Penny L. Post, Ph.D.
Vice President of Quality and Regulatory Affairs
Penny became Vice President of Regulatory and Quality in 2007. She has a strong background in biochemistry and protein purification. She joined the company in 2000 and has served various management roles within the company in the Process Development, Quality and Manufacturing departments. Penny has been involved in the development, manufacturing, product release and regulatory filing for recombinant proteins involved in diseases such as influenza and AIDS. Prior to joining PSC, Penny was a postdoctoral fellow and associate research scientist at Yale University.
Mark Michalik
Vice President of Operations
Mark joined Protein Sciences in 2007 as Vice President of Operations. For 20 years prior to joining the company, Mark held positions with Merck & Co. Inc. culminating as a Director with Merck Manufacturing Division. Mark has experience in Quality Control, Quality Assurance, Project and Supply Chain Management, Technology, and Manufacturing. Prior to joining PSC Mark held leadership positions with Merck & Co. in Bacterial Vaccine and Gardasil® Manufacturing.
Ljiljana Minwalla, Ph.D.
General Counsel / Secretary
Ljiljana joined Protein Sciences in 2009 as General Counsel / Secretary. For 4.5 years prior to joining the company, Ljiljana practiced as a registered patent attorney for biomedical and biotechnological patents and managed patent portfolios. She also prepared freedom-to-operate, invalidity, and patentability analyses and litigated patent cases. Ljiljana’s Ph.D. is in Pharmacology with a strong focus on cell biology. She was also a post-doctoral fellow at the New York University School of Medicine in Dermatology and Cell Biology.
Advisory Team
Thomas Kowalski
Patent Counselor
Thomas Kowalski is a partner in Frommer Lawrence & Haug LLP (www.FLHLaw.com), a full service U.S. intellectual property law firm, based in NYC, with offices in NYC, San Diego CA, and Tokyo. FLH handles all aspects of intellectual property law, including patent, trademark, and copyright prosecution, counseling, and litigation, and related matters, including regulatory/FDA matters.
John Treanor, MD
Medical Advisor/ Principal Investigator Clinical Trials
John Treanor is Professor of Medicine, Microbiology, and Immunology and Chief of the Division of Infectious Diseases at the University of Rochester Medical Center. He is a current or former member of the Microbiology and Infectious Diseases Research Advisory Committee (MIDRAC); Veteran's Administration Merit Review Board for Infectious Disease; and the CDC's Advisory Committee on Immunization Practice (ACIP). Dr. Treanor's current research interests are related to the clinical evaluation of vaccines and other control measures for human infectious diseases, including studies of novel vaccines for seasonal and pandemic influenza, evaluation of antiviral agents for influenza, and studies of the human immune response to influenza infection and vaccination.
Donna Chandler, Ph.D.
Regulatory Advisor
Donna Chandler is currently an independent consultant for vaccine and biologics development, after more than 28 years of service with FDA/USPHS. From 1997 until her retirement in November 2006, she was Deputy Director, Division of Vaccines and Related Products Applications, Office of Vaccines Research and Review, CBER, FDA. Dr. Chandler joined FDA in 1978, where she investigated Mycoplasma pneumoniae pathogenicity and animal models of disease and protection. In 1989, Dr. Chandler moved to the FDA's Division of Biologic INDs, where she was a senior regulatory reviewer of bacterial and viral vaccines, allergenic products, and immune globulins.
